JPMorgan Lowers Vivendi Price Target to EUR 2.90, Maintains Overweight Rating
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 01 2025
0mins
JPMorgan lowered the firm's price target on Vivendi to EUR 2.90 from EUR 3 and keeps an Overweight rating on the shares.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VIV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VIV
Wall Street analysts forecast VIV stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for VIV is 13.80 USD with a low forecast of 12.90 USD and a high forecast of 14.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
1 Buy
1 Hold
1 Sell
Hold
Current: 14.450
Low
12.90
Averages
13.80
High
14.50
Current: 14.450
Low
12.90
Averages
13.80
High
14.50
About VIV
Telefonica Brasil SA, formerly Telecomunicacoes de Sao Paulo SA TeleSP is a Brazil-based company active in the telecommunications sector. The Company’s main services include fixed-line, local and long-distance telephony; mobile telephony, including value-added services; data services, including fixed and mobile broadband, and pay television (TV), mainly Internet Protocol television (IPTV). Telefonica Brasil SA commercializes its services and solutions through the Vivo brand. The Company is a digital hub that facilitates its customers’ access to an array of services, such as entertainment, cybersecurity, finance, health, and education, in addition to providing fixed and mobile telecommunication services across Brazil. It also offers a complete and convergent portfolio for business-to-consumer (B2C) and business-to-business (B2B) clients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
New Global Stock Investment Strategy: Safe and Cheap Options
- Screening Strategy: By utilizing Benzinga's ranking system, investors can quickly identify stocks with reasonable valuations, thereby avoiding the risks associated with overvalued stocks and increasing the likelihood of investment success.
- Financial Health Check: The integration of the Piotroski F-Score allows investors to distinguish between low-valued stocks that are improving in fundamentals, thus reducing bankruptcy risks and enhancing investment safety.
- Global Market Opportunities: In the global market, investors should be aware of country risks and market structures, seeking out companies that are undervalued yet financially sound to achieve higher investment returns.
- Systematic Investment Process: Using the Benzinga Pro tool, investors can efficiently filter non-U.S. companies, combining value rankings with financial health indicators to create a systematic investment strategy that enhances the scientific basis of investment decisions.
Continue Reading
Court Ruling Favors Billionaire, Making Vivendi Takeover by Bollore Less Probable
- Court Ruling: A French court overturned a previous ruling that suggested Vincent Bollore's family had de facto control over Vivendi.
- Impact on Investors: The decision quashed investor hopes for a potential full takeover of the media group by Bollore following its four-way spinoff last year.
- Error in Lower Court: The highest court in France stated that a lower appeals court had made an error in its assessment of the family's control over Vivendi.
- Bollore Holding Company: The ruling specifically addressed the claims regarding the Bollore holding company's influence over Vivendi's operations.
Continue Reading